- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Neal Dave Expresses Excitement for the First PD-1 Inhibitor Biosimilar
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discussed physician anticipation for the first biosimilars for programmed death (PD)-1 inhibitors.
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discussed physician anticipation for the first biosimilars for programmed death (PD)-1 inhibitors.
Transcript:
Do you see much excitement in the oncology community for the arrival of biosimilars for PD-1 inhibitors?
Dave: Yes, I don't know when the patents expire on the PD-1 inhibitors. But yeah, when their patents are expiring for sure. Their indication list is so large, especially for some of them where you can use them in so many different types of cancers. There are some indications that are not specific to a type of cancer. It's just based on your genetic testing. So, it's very valuable to help decrease that cost. There are top drugs that were used, just because of all the indications that they have. And so, whenever a biosimilar comes out, it'll be an exciting time and, again, just like how we've had in the last few years with the 3 major biosimilars that have come out, it's significantly decreased the cost of therapy and I think the same thing will happen with PD-1 inhibitors.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More
